PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer care across a wide range of tumor types and disease ...

STING inhibits LINE-1 retrotransposition to maintain genomic stability in an IFN-independent manner. STING interacts with ...